Summary
Safety data have been gathered in US clinical trials of nabumetone on 1912 patients from August 1981 to May 1988. Dosing in the double-blind trials was 100mg at bedtime, but in open-label trials patients could increase the dosage of nabumetone to 1500 or 2000mg if required. Adverse experiences reported in the double-blind and open-label studies that were considered related to nabumetone treatment, or of unknown origin, occurred most commonly in two body systems: the body as a whole, and the digestive system. Incidence rates greater than 10% for adverse experiences categorised by preferred term occurred in the ‘body as a whole’ category for abdominal pain, and in the digestive system for diarrhoea and dyspepsia. Dosage increases to 2000mg appeared to cause a dose-related increase in diarrhoea. In the long term studies, gastrointestinal ulcers have been confirmed in 13 (0.7%) patients. Hepatic and renal function was well preserved in patients treated with nabumetone. Overall, only 7 nabumetone-treated patients (0.4%) showed a marked elevation in both ALT (SGPT) and AST (SGOT). Two nabumetonetreated patients showed marked elevations in renal parameters, serum creatinine and blood urea nitrogen. Overall, nabumetone was well tolerated, and the adverse experience profile was clinically acceptable and presented no unusual or unexpected patterns.
Similar content being viewed by others
References
Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal anti-inflammatory drugs. New England Journal of Medicine 310: 563–572, 1984
Greb W, von Schrader H, Cerlek S, Dominis M, Hauptmann E, et al. Endoscopic studies of nabumetone in patients with rheumatoid arthritis: a comparative endoscopic and histologie evaluation. American Journal of Medicine 83(4B): 19–24, 1987
Lussier A, LeDel E. Radiochromium (chromium-51) evaluation of gastrointestinal blood loss associated with placebo, aspirin and nabumetone. American Journal of Medicine 83(4B): 15–18, 1987
McMahon F, Verges R, Ryan J, Fitts D. Nabumetone kinetics in the young and elderly. American Journal of Medicine 83(4B): 92–95, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Willkens, R.F. An Overview of the Long Term Safety Experience of Nabumetone. Med Toxicol Adverse Drug Exp 40 (Suppl 5), 34–37 (1990). https://doi.org/10.2165/00003495-199000405-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199000405-00008